Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elobixibat (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Proof of concept; Therapeutic Use
Sponsors Albireo Pharma

18 Aug 2020 According to an Albireo Pharma media release, based on the results of this study, company has made the decision not to pursue further development of elobixibat in NASH.
18 Aug 2020 According to an Albireo Pharma media release, primary endpoint (Change from baseline in serum low-density lipoprotein cholesterol (LDL-C) at Week 16 time_frame: Week 16) has been met.
18 Aug 2020 Results presented in a Albireo Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com